Grace Therapeutics, Inc. (GRCE) Operating income 2019–2026
Grace Therapeutics, Inc. (GRCE) annual operating income history from SEC filings — each fiscal year as reported.
-$11.1MFY2026 · since FY2019: -$34.4M → -$11.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$11.1M | +33.6% |
| FY2025 | -$16.7M | -29.8% |
| FY2024 | -$12.9M | +75.4% |
| FY2023 | -$52.2M | -234.6% |
| FY2022 | -$15.6M | +5.1% |
| FY2021 | -$16.4M | +32.8% |
| FY2020 | -$24.4M | +29.0% |
| FY2019 | -$34.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GRCE financial trends
GRCE RevenueGRCE Net incomeGRCE Net marginGRCE Gross profitGRCE Gross marginGRCE Operating marginGRCE Operating cash flowGRCE Free cash flowGRCE Capital expendituresGRCE Return on equityGRCE Stock buybacksGRCE Dividends paidGRCE Total assetsGRCE Total liabilitiesGRCE Shareholders’ equityGRCE overview →